Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H22N2O3.2ClH |
| Molecular Weight | 339.258 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.COC1=C(OC)C(OC)=C(CN2CCNCC2)C=C1
InChI
InChIKey=VYFLPFGUVGMBEP-UHFFFAOYSA-N
InChI=1S/C14H22N2O3.2ClH/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16;;/h4-5,15H,6-10H2,1-3H3;2*1H
| Molecular Formula | C14H22N2O3 |
| Molecular Weight | 266.3361 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Trimetazidine is a medicine, which is used for the treatment of angina pectoris. The drug mechanism of action is explained by its ability to selectively inhibit long-chain 3-ketoacyl coenzyme A thiolase, an enzyme responsible for mitochondrial beta-oxidation of long chain fatty acids. Trimetazidine also increases pyruvate dehydrogenase activity, binds to the mitochondrial membrane, directly inhibits cardiac fibrosis and improves mechanical resistance of the sarcolemma.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P55084 Gene ID: 3032.0 Gene Symbol: HADHB Target Organism: Homo sapiens (Human) |
75.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | VASTAREL Approved UseTrimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies. Launch Date2012 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Trimetazidine reduces basal cytosolic Ca2+ concentration during hypoxia in single Xenopus skeletal myocytes. | 2003-05 |
|
| Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure. | 2003-05 |
|
| Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. | 2003-04-16 |
|
| Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy. | 2003-04-08 |
|
| Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. | 2003-04 |
|
| Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. | 2003-04 |
|
| Metabolic modulation and optimization of energy consumption in heart failure. | 2003-03 |
|
| Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine. | 2003-03 |
|
| Prevention of heart failure in rats by trimetazidine treatment: a consequence of accelerated phospholipid turnover? | 2003-03 |
|
| Trimetazidine effect on phospholipid synthesis in ventricular myocytes: consequences in alpha-adrenergic signaling. | 2003-02 |
|
| Effects of trimetazidine on acetic acid-induced colitis in female Swiss rats. | 2003-01-24 |
|
| Attenuation of glycerol-induced acute renal failure in rats by trimetazidine and deferoxamine. | 2003-01 |
|
| [Effect of treatment with trimethazidine on characteristics of arrhythmia and indicators of heart rhythm in patients with chronic cardiac failure]. | 2003 |
|
| [Effects of trimetazidine on serum oxygen free radicals in congestive heart failure]. | 2002-12-28 |
|
| Cardioprotective effect of trimetazidine during thrombolytic therapy in patients with acute myocardial infarction. | 2002-12 |
|
| [Coronary artery disease observed in general hospitals: ETTIC study. Comparison between trimetazidine and mononitrate isosorbide for patients receiving betablockers]. | 2002-11 |
|
| The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. | 2002-11 |
|
| Protective effect of trimetazidine in a model of ischemia-reperfusion in the rat retina. | 2002-10-17 |
|
| Bioavailability studies on guar gum-based three-layer matrix tablets of trimetazidine dihydrochloride in human volunteers. | 2002-10-04 |
|
| Effects of trimetazidine on tissue damage in kidney after hindlimb ischemia-reperfusion. | 2002-10 |
|
| Metabolic plasticity and the promotion of cardiac protection in ischemia and ischemic preconditioning. | 2002-09 |
|
| [Oxygen dependent metabolism of neutrophils and monocytes in patients with unstable angina and its correction with preductal]. | 2002-08-03 |
|
| Trimetazidine: a second look. Still no efficacy in visual disorders. | 2002-08 |
|
| [The role of endogenous modulators of chemoreactivity in the regulation of coronary blood flow]. | 2002-07 |
|
| Three-layer guar gum matrix tablet formulations for oral controlled delivery of highly soluble trimetazidine dihydrochloride. | 2002-05-17 |
|
| Recognition forces involved in mitochondrial binding to a low-affinity trimetazidine binding site related to anti-ischemic activity. | 2002-05-01 |
|
| New concepts in organ preservation. | 2002-05 |
|
| Oxidative stress-mediated renal dysfunction by cyclosporine A in rats: attenuation by trimetazidine. | 2002-05 |
|
| Partial fatty acid oxidation inhibitors for stable angina. | 2002-05 |
|
| Gateways to Clinical Trials. | 2002-04 |
|
| Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective. | 2002-04 |
|
| Energy metabolism in the hypertrophied heart. | 2002-04 |
|
| Cardioprotection of trimetazidine and anthracycline-induced acute cardiotoxic effects. | 2002-03-30 |
|
| Last performance with VIAGRA: post-mortem identification of sildenafil and its metabolites in biological specimens including hair sample. | 2002-03-28 |
|
| Trimetazidine as a potential neuroprotectant in transient global ischemia in gerbils: a behavioral and histological study. | 2002-02-22 |
|
| [The study and comparative evaluation of the actoprotective activity of ATF-LONG in experiment]. | 2002 |
|
| [Antiischemic efficacy of trimetazidine in patients with ischemic heart disease, stable angina pectoris and disturbances of carbohydrate metabolism]. | 2002 |
|
| [Efficacy of trimetazidine in stable angina pectoris refractory to traditional treatment]. | 2002 |
|
| [Trimetazidine in correction of chronic heart failure in patients with ischemic heart disease]. | 2002 |
|
| [Trimetazidine in pectoris patients older than 65 years with stable angina]. | 2002 |
|
| [Use of trimetazidine in the combined therapy of myocardial infarction with left ventricular dysfunction]. | 2002 |
|
| [Significance of trimetazidine for out of hospital physical rehabilitation after myocardial infarction]. | 2002 |
|
| Trimetazidine limits the effects of myocardial ischaemia during percutaneous coronary angioplasty. | 2002 |
|
| [Decrease in the sensitivity to the anti-ischemic effect of propranolol and prospects for correcting it in patients with stable angina pectoris]. | 2002 |
|
| [Effect of atenolol and trimetazidine on dispersion of cardiac rhythm in patients with moderately expressed postinfarction left ventricular dysfunction]. | 2002 |
|
| [Enhancement of antioxidant status of the elderly patients with ischemic heart disease in response to amino acid composition of MP-33 in combined therapy with trimetazidine]. | 2002 |
|
| Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. | 2001-12 |
|
| Can metabolic manipulation reverse myocardial dysfunction? | 2001-12 |
|
| [Metabolic considerations in the treatment of coronary disease in diabetic patients]. | 2001-11 |
|
| Management of ischaemic heart disease in diabetic patients--is there a role for cardiac metabolic agents? | 2001 |
Patents
Sample Use Guides
The dose is one tablet of 20 mg of trimetazidine three times a day or 35 mg twice a day during meals.
Route of Administration:
Oral
Rat cardiomyocytes were treated with trimetazidine (1-5*10(-4) M final concentration) in the bath. Then the cells were submitted either to 150 min normoxia or to 150 min hypoxia followed by 90 min reoxygenation in the absence of oxidizable substrate. The drug (at 5*10(-4) M) was efficient in protecting the isolated cardiac myocytes against the functional alterations induced by substrate-free hypoxia and led thus to a better recovery upon reoxygenation.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:29:33 GMT 2025
by
admin
on
Mon Mar 31 21:29:33 GMT 2025
|
| Record UNII |
48V6723Z1P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
236-117-0
Created by
admin on Mon Mar 31 21:29:33 GMT 2025 , Edited by admin on Mon Mar 31 21:29:33 GMT 2025
|
PRIMARY | |||
|
m11144
Created by
admin on Mon Mar 31 21:29:33 GMT 2025 , Edited by admin on Mon Mar 31 21:29:33 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL203266
Created by
admin on Mon Mar 31 21:29:33 GMT 2025 , Edited by admin on Mon Mar 31 21:29:33 GMT 2025
|
PRIMARY | |||
|
SUB90444
Created by
admin on Mon Mar 31 21:29:33 GMT 2025 , Edited by admin on Mon Mar 31 21:29:33 GMT 2025
|
PRIMARY | |||
|
DBSALT001114
Created by
admin on Mon Mar 31 21:29:33 GMT 2025 , Edited by admin on Mon Mar 31 21:29:33 GMT 2025
|
PRIMARY | |||
|
100000091242
Created by
admin on Mon Mar 31 21:29:33 GMT 2025 , Edited by admin on Mon Mar 31 21:29:33 GMT 2025
|
PRIMARY | |||
|
13171-25-0
Created by
admin on Mon Mar 31 21:29:33 GMT 2025 , Edited by admin on Mon Mar 31 21:29:33 GMT 2025
|
PRIMARY | |||
|
759317
Created by
admin on Mon Mar 31 21:29:33 GMT 2025 , Edited by admin on Mon Mar 31 21:29:33 GMT 2025
|
PRIMARY | |||
|
SUB12374MIG
Created by
admin on Mon Mar 31 21:29:33 GMT 2025 , Edited by admin on Mon Mar 31 21:29:33 GMT 2025
|
PRIMARY | |||
|
48V6723Z1P
Created by
admin on Mon Mar 31 21:29:33 GMT 2025 , Edited by admin on Mon Mar 31 21:29:33 GMT 2025
|
PRIMARY | |||
|
83201
Created by
admin on Mon Mar 31 21:29:33 GMT 2025 , Edited by admin on Mon Mar 31 21:29:33 GMT 2025
|
PRIMARY | |||
|
DTXSID1045407
Created by
admin on Mon Mar 31 21:29:33 GMT 2025 , Edited by admin on Mon Mar 31 21:29:33 GMT 2025
|
PRIMARY | |||
|
235779
Created by
admin on Mon Mar 31 21:29:33 GMT 2025 , Edited by admin on Mon Mar 31 21:29:33 GMT 2025
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
correction factors: for the calculation of contents, multiply the peak areas of the following impurities by the corresponding correction factor: impurity B = 0.55
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
correction factors: for the calculation of contents, multiply the peak areas of the following impurities by the corresponding correction factor: impurity F = 0.71
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
correction factors: for the calculation of contents, multiply the peak areas of the following impurities by the corresponding correction factor: impurity C = 0.37
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |